Osage University Partners has returned to back the cancer and inflammatory drug developer based on research from multiple universities.
Ribon Therapeutics, a US-based oncology drug developer based on research at Massachusetts Institute of Technology (MIT), University of Texas (UT) Southwestern Medical Centre and Harvard University’s Harvard Medical School, has secured $65m in funding from investors including Osage University Partners (OUP).
Investment firm Deerfield Management and venture capital firm US Venture Partners (USVP) co-led the round, which also included corporates Alphabet, AbbVie, Bristol Myers Squibb, Johnson & Johnson, Novartis and Takeda.
Avego BioScience Capital, Monashee Investment…
Avego BioScience Capital, Monashee Investment…
